Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tridem Bioscience Alzheimer's vaccine
- Development stage
- Preclinical
- Lead developer
- Tridem Bioscience
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intraperitoneal
01
Overview
Tridem Bioscience is developing a therapeutic neoglucoconjugate vaccine for the treatment of Alzheimer's Disease. Utilizing the proprietary WISIT (Weak Immunogen Specific Immunotherapy) platform, the vaccine is designed as an active immunotherapy to induce the production of endogenous antibodies against amyloid-beta (Aβ). The goal of this approach is to stimulate the patient's immune system to recognize and clear Aβ peptides, thereby reducing amyloid pathology and plaque accumulation in the brain. The program is currently in the discovery phase.
- Other names
- Aβ neoglucoconjugate vaccineWISIT Aβ vaccineTridem Bioscience-Aβ (Amyloid beta)-therapeutic neoglucoconjugate vaccine
02
Targets
Aβ (Amyloid-beta peptides and aggregates)
Beyond the preview
Go deeper on Tridem Bioscience Alzheimer's vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tridem Bioscience Alzheimer's vaccine.